Not a notes website. Not a question bank. A structured system that builds the subspecialist reasoning required to pass the EFRM — and practise at the level it demands.
Same concept · 5 angles · Subconscious encoding
PICO framework · ESHRE benchmarking · Real cases
Adversarial probing · 7-station mastery · Evidence anchoring
6–8 week cohort · Error loop · Clinical thinking architect
Core Innovation
Inspired by the film Vantage Point — same event, different observers, different experience. One concept tested from five completely different clinical angles. Not pattern recognition. Subconscious encoding.
If a mock uses the same clinical wording, same patient demographics, same diagnostic structure — your brain switches from concept retrieval to pattern recognition. Mock scores inflate. Exam performance drops. The brain sees "PCOS + AMH 8 + IVF" and clicks antagonist protocol without thinking. That is not reasoning. That is recall. The EFRM exam deliberately rotates vantage points to break this — and so does this system.
Secreted by granulosa cells of small antral follicles. Reflects the recruitable pool — not total primordial reserve. AMH does not fluctuate across the menstrual cycle.
AMH 0.7 ng/ml + AFC 4 = POSEIDON Group 3. Antagonist protocol, consider adjuvant LH, dual trigger discussion — clinical translation of a number into a decision.
When AMH appears as a primary outcome in an RCT — is it patient-relevant or a surrogate? What is its clinical translation threshold? Does a 20% change in AMH matter to the patient?
Endometrioma cystectomy vs ablation — differential impact on AMH. Surgical counselling implications. When does fertility preservation need to happen before surgery?
Reverse reasoning — instead of "what does low AMH mean", the question asks who falls outside the model. Patients with discordant AMH/AFC, premature luteinisation, or prior ovarian surgery may not follow the standard prediction curve. The exam tests whether you know the boundaries of the concept, not just its centre.
The principle: One concept — AMH — tested across five stations, five clinical contexts, five different reasoning frameworks. A candidate who memorised "AMH = ovarian reserve" will fail Vantages 3, 4, and 5. This system ensures you see every concept from every angle before the exam does. The goal is not 90%+ mock scores. The goal is decision stability under pressure and fatigue — when the question looks unfamiliar but the concept is not.
Part 1 — Written Examination
Part 1 is the conceptual bedrock. 90 questions across two papers — SBA and EMQ — testing knowledge depth before you reach the OSCE. The same vantage-point architecture applies here.
2 papers · 45Q each · Paper 1: 25 SBA + 20 EMQ · Paper 2: 25 SBA + 20 EMQ · No mid-section answers
Each concept appears across multiple stems with different language, different patient demographics, different framing — the same architecture as the OSCE.
Every wrong answer: Question trigger → Core concept → ESHRE exam rule. The error log drives next-session content. Adaptive correction, not volume.
Part 1 preparation is covered in the mentorship cohort (Weeks 1–5). Full OSCE preparation (Part 2) is the dominant focus of this platform. Explore the OSCE system → or join the cohort for the complete pathway.
You are building cognitive endurance — the ability to reason clearly through unfamiliar clinical presentations under fatigue and uncertainty. That is what the EFRM tests. That is what this system trains.
The OSCE is not a communication exam. It is an oral viva with a written trigger — assessing whether you think like a European reproductive medicine subspecialist.
The Critical Distinction
Examiners classify each candidate per station as Pass / Borderline / Fail. The pass mark equals the median of borderline candidates — calculated independently for each station. You cannot compensate a weak station with strength elsewhere. Every station must independently clear its own bar.
Station Map
Each station is a separate clinical universe. Your IVF background gives natural strength in 3 — but every station must clear its own threshold independently. No exceptions.
PCOS, POI, thyroid, prolactin, amenorrhoea. Every answer anchored to ESHRE guideline thresholds — not memory.
Least IVF-adjacent. Genital anomalies, puberty disorders — requires focused reading from first principles.
Lab meetings, PGT, chromosomal mosaicism — close to your daily clinical language. Structured answers needed.
Ectopic, miscarriage, RIF, RPL. Cross-reference ESHRE and NICE — every threshold and algorithm matters.
Your home ground. IVF protocols, OHSS, stimulation — translate daily experience into structured, evidence-referenced viva answers.
Oncofertility, social freezing, surgical thresholds. Your clinical cycles give you the narrative — the system gives it structure.
The hidden differentiator. Critical appraisal — design, statistics, bias, clinical translation. The question is never "what did this study show" — it is "should this change your practice, and why?"
Daily Practice — 17:30–18:00
Not a role-play session. A viva practice session. The self-interrogation step (Step 3) is what most candidates skip — and what the examiner will actually do to you.
Silent reading 1–2 min. Identify core clinical question, key data, red flags. Do not speak yet.
7-step algorithm. Every answer must contain "According to ESHRE guidelines…" — without this, evidence-anchoring marks are lost.
Act as the examiner. "Why not option B?" · "What if AMH was 0.5?" · "What does ESHRE say exactly?" · "What if she fails first-line?" Pre-empt every adversarial probe.
Look up the ESHRE guideline. Compare point-by-point. Every gap written down — the gap log drives the next session's content.
Why not IUI first — what does ESHRE say about the threshold for proceeding directly to IVF?
AMH is now 0.5 pmol/L. Does that change your stimulation protocol?
She fails two IVF cycles. What is your next conversation with her?
PCOS by Rotterdam — she meets 2 of 3 criteria. Which two? Does the combination matter clinically?
TSH is 3.8. Do you treat before IVF? What is the ESHRE threshold?
POI at age 32 — what is the evidence base for HRT vs combined oral contraceptive?
Three consecutive miscarriages — what investigations does the ESHRE RPL guideline mandate first-line?
At what point does ESHRE define recurrent implantation failure?
HCG is plateauing — not rising, not falling. Walk me through your algorithm.
The p-value is 0.04 but confidence intervals cross 1. What does that tell you?
Single-centre study, n=120. Would you change your practice based on this alone?
The authors declare no conflict of interest but the intervention is proprietary. How does that affect your interpretation?
The examiner rewards intellectual honesty paired with clinical safety. Never bluff. Never say "I'm not sure." Frame uncertainty the way a subspecialist does.
RCT, cohort, case-control, systematic review? Appropriate for the clinical question?
Well-defined? Inclusion/exclusion appropriate? Generalisable to your patients?
Clearly described and reproducible? Could another clinician replicate it exactly?
Patient-relevant or surrogate? Pre-specified or post-hoc? Does it matter to the patient?
P-value vs confidence intervals? Absolute vs relative risk? NNT calculated?
Selection, performance, detection, attrition? Confounding accounted for?
Match the data? Overclaimed? Underclaimed? Conflicts of interest declared?
Should this change your practice? Why or why not? What would need to be true?
Always close Station 7 with: "Based on the methodological limitations of this study, I would [not change / cautiously consider / adopt] this approach — and I would be more persuaded by a [multicentre RCT / larger sample / longer follow-up] before routinely adopting it." That single sentence signals clinical translation, not just appraisal.
Most mentorships dump content and solve doubts. This cohort builds a clinical reasoning system — the cognitive infrastructure to pass the EFRM and practise at subspecialist level.
What this is NOT / IS
Doubt solving · Notes sharing · Casual WhatsApp guidance · Content dumping · Teaching facts · Solving questions after the fact
Structured clinical mentorship pathway to EFRM · Correcting thinking patterns · Simplifying decision-making · Translating concepts into clinical logic · Building reasoning architecture
Weekly Structure — Fixed Template
Foundation topic with structured guide. Output: What you must KNOW. Anchored to ESHRE guideline. No excess — only high-yield.
Real-world scenarios. Protocol selection. Decision pathways. This is where the system differentiates — concept becomes clinical action.
15–25 SBA/EMQs per week. Same concept, multiple angles, different language. Concept rotation matrix. No déjà vu — deliberate.
You submit mistakes and confusions. Pattern correction and thinking error identification. This activates the error notebook system.
8-Week Programme
A structured pathway from orientation to full OSCE simulation. Each week builds on the last — concept depth before clinical application before exam pressure.
Understand the EFRM system. How to think — not what to read. Basic reproductive physiology. Vantage-point system introduced.
AMH, AFC, FSH threshold, feedback loops. Poor responder vs normal vs high responder classification. POSEIDON framework.
Antagonist vs agonist protocols. Trigger strategies — hCG, GnRHa, dual trigger. OHSS prevention hierarchy. Freeze-all decision.
Fertilisation, cleavage timing, blastocyst development, embryo grading, vitrification, biopsy for PGT. Istanbul consensus criteria.
IUI vs IVF vs ICSI indications. FET protocol selection — natural cycle vs modified vs HRT. Luteal phase support evidence.
Endometrial receptivity, RIF definition, uterine pathology hierarchy. Adjuncts — evidence vs hype. RPL investigations and management.
1 complete mock OSCE — all 7 stations. Timed viva with structured feedback. Adversarial probing on every answer. No halfway.
Error notebook deep review. Weak area targeting. Concept inversion questions — testing the boundaries, not the centre. Final readiness assessment.
Cohort Details
Benchmarked vs ESHRE · RCOG · NICE
Every clinical decision in this real case mapped to a PICO question and guideline verdict. This is how the EFRM examiner will dissect your cases — and how the mentorship system trains you to think.
1×1cm fluid near scar · Patient declined hysteroscopy · Fluid resolved Day 5
In patients with previous LSCS scar defect with intrauterine fluid, does hysteroscopic assessment before FET improve implantation and live birth rates?
ESHRE RIF guideline 2023 — uterine cavity assessment recommended before FET in suspected pathology. Key clinical rule: intracavitary fluid on ET day = cancel transfer. The monitoring plan (reassess serially, cancel if fluid persists) was the correct response to informed refusal.
Retrospectively justified. Fluid resolved by Day 5. Monitoring plan was correct — patient autonomy respected after documented counselling. Its absence at Day 5 validated continuation of the cycle.
Ovulatory patient · Regular cycles · Physiological approach
In ovulatory patients undergoing FET, does natural cycle FET achieve equivalent live birth rates to HRT-FET?
Guideline-aligned. ESHRE FET preparation guideline 2022 — natural cycle FET is preferred in ovulatory women. NEET trial confirms comparable or superior outcomes vs HRT-FET.
Day 12 · Follicle 21mm · Converts NC-FET to mNC-FET
In natural cycle FET where ET is <8mm, does estradiol supplementation improve ET and clinical outcomes?
Evidence base is mixed — no strong RCT support. The more evidence-aligned alternative at Day 12 with follicle 21mm was triggered NC-FET — explicitly ESHRE-endorsed. ET reached 8.1mm Day 14 — the goal was achieved pragmatically.
Clinically justified deviation. OSCE answer: acknowledge mNC-FET conversion, name triggered NC-FET as the stronger evidence-based alternative, cite specific clinical justification — 3 LSCS limiting total uterine attempts, high-value embryos.
Elective SET · USG-guided · Tenaculum under sedation · 1.5cm from fundus
In NC-FET, should P+5 be counted from spontaneous ovulation or from start of exogenous progesterone?
From spontaneous ovulation — not from exogenous progesterone start date. Ovulation confirmed 4/4/26. Transfer 9/4/26 = P+5 from ovulation = correct. Pre-planned tenaculum + mild sedation for known cervical stenosis = excellent preparation for a predictable problem.
Excellent technical management. USG guidance + 1.5cm fundal placement + catheter recheck empty — all ESHRE good practice confirmed. eSET was the only appropriate decision given 3 LSCS scar risk.
4AA pre-freeze → Significant blastocoele collapse at 40× view · 11am · Transfer 12pm
Should a significantly collapsed blastocyst not re-expanding at 16–18 hours post-thaw be transferred or offered extended culture?
ESHRE Vienna Consensus: blastocysts failing to re-expand by 18–24hrs have significantly reduced implantation potential. Biological mechanism: Na-K-ATPase-driven blastocoele re-accumulation requires intact TE tight junctions + mitochondrial energy — collapse suggests disruption of either. The critical window was 11am → 12pm. Re-expansion status at loading is the decisive data point.
The key variable. Uterine environment optimal (ET 8.1mm, P4 30 ng/ml). If re-expansion occurred 11–12pm: implantation probability 35–45%. If still collapsed at loading: 15–25%. The embryo is the limiting factor.
Vantage-Point System Applied
The same clinical events generate different examiner questions depending on which station you are in. This is the vantage-point system in action — one case, multiple angles, multiple stations.
The 40× image shows significant blastocoele collapse at 11am. Transfer is at noon. What is your immediate action?
Model answer: The 40× image is the diagnostically reliable view — significant collapse, no visible blastocoele cavity at 16–17 hours. This does not yet meet re-expansion criteria per ESHRE Vienna Consensus. Immediate action: return to incubator, reassess every 30–60 minutes. Inform the patient that transfer may be delayed 1–2 hours or that we may proceed with a partially compromised embryo. Biological basis: failure of Na-K-ATPase-driven blastocoele re-accumulation due to TE tight junction disruption or mitochondrial dysfunction post-vitrification. Document the discussion contemporaneously.
You added estradiol in what started as a natural cycle. How do you classify this cycle, and what evidence supports your decision?
Model answer: Adding exogenous estradiol converts true NC-FET to modified natural cycle FET — mNC-FET. Evidence base for this specific intervention is limited with no strong RCT data. The more evidence-aligned option at Day 12 with a 21mm follicle was triggered NC-FET — explicitly endorsed in ESHRE guidance. Clinical justification was compelling: 3 previous LSCS limiting total uterine attempts, high-value frozen embryos, borderline ET. Document as a clinically indicated protocol modification and acknowledge the deviation in the cycle summary.
βhCG returns 180 IU/L on 19/4. What is your immediate management plan?
Model answer: Positive result at 10 days post-blastocyst transfer. Immediate priorities: first, serial βhCG at 48hrs to confirm ≥66% rise. Second, early viability scan at 6–7 weeks — crucially, in 3 LSCS + bilateral tubal ligation, I need to confirm intrauterine location and exclude scar implantation given the Day 2 fluid history. Third, scar thickness assessment at this early scan. Escalate to MDT — obstetric medicine and maternal-fetal medicine — from first positive result. Consultant-led care, planned 4th LSCS at 37–38 weeks, screening for placenta accreta spectrum from 16 weeks.
Optimal uterine environment — ET 8.1mm, P4 30 ng/ml, P+5 timing, elective SET. The variable is post-thaw re-expansion. Regardless of the result — the reasoning system has been built. The learning is locked in.